Vor Biopharma Inc. (VOR) Stock Forecast
VOR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 9 analysts
- Price target
- $39.00 average of analyst targets
- Upside to target
- +116.3% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.81
- 52-week range
- $6.86 – $29.43
VOR analyst ratings
9 analystsNumber of analysts at each rating.
VOR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VOR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.72 | −$0.72 | −$0.72 | −$121.63 | +99.4% | 1 |
| Current fiscal year (2026) | −$6.53 | −$6.53 | −$6.53 | −$70.50 | +90.7% | 1 |
| Next fiscal year (2027) | −$3.80 | −$4.50 | −$2.93 | −$6.53 | +41.9% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VOR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
VOR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VOR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$0.72 | −$0.72 | −$0.72 | −$0.72 | −6.2% | 1 up · 1 down |
| Current fiscal year (2026) | −$6.90 | −$6.53 | −$6.53 | −$6.53 | −$6.53 | −5.4% | 1 up · 1 down |
| Next fiscal year (2027) | −$3.74 | −$3.81 | −$3.81 | −$3.82 | −$3.80 | +1.5% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VOR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VOR beat in 4 of 12.
What analysts expect from VOR
9 analysts cover Vor Biopharma; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $39.00, 116.3% above the latest close of $18.03. Analysts expect earnings of −$6.53 per share for 2026, +90.7% from a year earlier. For 2027 the average estimate is −$3.80 per share. Vor Biopharma beat the EPS estimate in 4 of the last 12 quarters.
Related: VOR income statement, VOR key metrics, VOR chart. See the VOR stock overview for the latest quote and news.
VOR forecast FAQ
What is Vor Biopharma's price target?
The average analyst price target for Vor Biopharma is $39.00, 116.3% above the latest close of $18.03.
Is Vor Biopharma a buy, hold or sell?
Of 9 analysts covering Vor Biopharma, 7 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vor Biopharma's EPS forecast?
Analysts forecast −$6.53 per share for 2026 (range −$6.53 to −$6.53); for 2027 the estimate is −$3.80.
When does Vor Biopharma report earnings?
Vor Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.81.
Does Vor Biopharma usually beat earnings estimates?
Vor Biopharma reported EPS at or above the analyst estimate in 4 of the last 12 quarters.